This 2013 review discusses the clinical use of androgen therapy in women, particularly for those experiencing hypoactive sexual desire disorder (HSDD). It highlights the role of androgens in sexual function, behavior, and cognition, noting that adrenal androgens may influence sexual symptoms and cognitive function in postmenopausal women. The article emphasizes
This 2015 review article examines hypoactive sexual desire disorder (HSDD), the most prevalent form of female sexual dysfunction, particularly among midlife women. It explores the multifactorial etiology encompassing biological, psychological, and social factors, including health status, depression, medications, relationship dissatisfaction, and history of abuse. The article discusses the transition from
This review explores the neurobiological mechanisms of bremelanotide, a melanocortin receptor (MCR) agonist, in treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide activates MC4Rs in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release and enhancing sexual desire. The review discusses how neurotransmitters like norepinephrine and
Bremelanotide, a melanocortin receptor agonist, has been FDA-approved as an as-needed treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Clinical trials demonstrated statistically significant improvements in sexual desire and reductions in distress related to low libido, though the overall clinical benefit was considered modest. Administered via subcutaneous injection
This study evaluated the long-term safety and efficacy of bremelanotide, a melanocortin receptor agonist, for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. A total of 684 participants completed a 24-week double-blind core phase before entering a 52-week open-label extension. Improvements in sexual desire were sustained, with FSFI-desire scores
Bremelanotide, a melanocortin receptor agonist, has shown statistically significant improvements in sexual desire and reduced distress related to hypoactive sexual desire disorder (HSDD) in premenopausal women. Administered as a subcutaneous injection on an as-needed basis, it provides an on-demand treatment option. However, the overall clinical benefit is modest, and nausea
Two phase 3 randomized, double-blind, placebo-controlled trials evaluated the safety and efficacy of bremelanotide, a melanocortin receptor agonist, for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. The trials included 1,267 participants, primarily white and U.S.-based, who received a 1.75 mg subcutaneous injection as needed before sexual activity. Bremelanotide
A review published in The Journal of Sexual Medicine examined the role of testosterone therapy in managing hypoactive sexual desire disorder (HSDD) in postmenopausal women. The study found that testosterone treatment significantly improves sexual desire and satisfaction in this population. However, potential side effects such as hirsutism and acne were
This review explores the efficacy and safety of testosterone therapy in treating hypoactive sexual desire disorder (HSDD) in postmenopausal women. Findings from large randomized, placebo-controlled trials indicate that transdermal testosterone significantly improves sexual desire, activity, and reduces distress related to sexual dysfunction. While most studies combined testosterone with estrogen/progesterone therapy,
This position statement by The North American Menopause Society (NAMS) evaluates the efficacy and safety of testosterone therapy in postmenopausal women, particularly for treating hypoactive sexual desire disorder (HSDD). Testosterone therapy has been associated with improvements in sexual desire, arousal, and satisfaction, though potential adverse effects include hirsutism, acne, and
